- $247.92bn
- $273.75bn
- $54.07bn
- 91
- 36
- 61
- 68
REG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - H1 and Q2 2025 results
AnnouncementREG - AstraZeneca PLC - Gefurulimab nanobody met Phase III endpoints
AnnouncementREG - AstraZeneca PLC - AstraZeneca plans to invest $50bn in the US
AnnouncementREG - AstraZeneca PLC - Update on anselamimab in AL amyloidosis
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpt in BaxHTN PhIII trial
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in the EU for bladder cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Datroway approved in US for EGFRm lung cancer
AnnouncementREG - Niox Group PLC AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - AstraZeneca enters into collaboration with CSPC
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Fixed-duration Calquence approved in EU for 1L CLL
Announcement